PCAC
PCAC (the FDA’s Pharmacy Compounding Advisory Committee) is the advisory body that reviews substances nominated for the compounding bulks lists and recommends whether pharmacies should be allowed to compound with them.
- FDA advisory committee for compounding bulks-list nominations
- Votes are recommendations — rulemaking makes them law
- July 2026: six of seven peptides received favorable votes
- Favorable votes change expectations, not legality
What PCAC actually decides — and what it doesn’t
PCAC reviews nominations to the 503A and 503B bulks lists, hears FDA staff analysis of safety and efficacy evidence, and votes recommendations. The votes are advisory: the FDA decides whether to adopt them through rulemaking, can decline to follow its committee, and often takes years to finalize. A favorable vote changes market expectations immediately and legal reality not at all — the distinction most headlines miss.
Why operators watch PCAC meetings
Because bulks-list status decides what compounded therapies can exist. The July 2026 meeting — where six of seven nominated peptides including BPC-157 and TB-500 received favorable votes against the FDA’s own reviewers’ advice — is the current case study: it signaled a pathway for compounded peptides while changing nothing about what programs may lawfully offer until rulemaking and compliant supply land. Programs in compounding-adjacent categories treat PCAC calendars the way public companies treat earnings dates.
How a nomination becomes a listed substance
The pipeline runs: nomination (typically by compounders or industry groups, with supporting data) → FDA staff review of safety, efficacy, and physical characterization → a public PCAC meeting and advisory vote → proposed rulemaking → final rule adding the substance to the bulks list — at which point compounding it becomes lawful with compliant sourcing. Each stage has its own clock; the rulemaking steps historically take the longest. Substances can also enter Category 1 of the interim evaluation, where the FDA exercises enforcement discretion while review proceeds — the basis on which NAD+ and sermorelin are compounded today.
Compliance handled, so you can build
Lithos runs the clinicians, pharmacies, and 50-state rules behind your care program — one API.
Frequently asked questions
Does a PCAC vote make a substance compoundable?
No. Only the FDA’s subsequent rulemaking does — a process that commonly runs a year or more, and the agency can decline to follow the committee.
Who nominates substances to PCAC?
Industry groups, compounders, and other stakeholders nominate; FDA staff review the evidence and present analysis before the committee votes.
What happened at the July 2026 meeting?
Six of seven nominated peptides — including BPC-157, TB-500, and KPV — received favorable 503A recommendations; emideltide did not. All votes were close and all remain advisory.